Immatics Raises Series B

Immatics Biotechnologies GmbH, a Tuebingen, Germany-based developer of immunotherapies for cancer treatment, has raised Euro 40 in second-round funding. Dietmar Hopp, the National Technology Enterprises Co. and KfW were joined by return backers 3i Group and Wellington Partners. www.immatics.com